Hyperoxaluria

• EMA approval · 2025-10-13
  EMA Authorised: Oxlumo (Lumasiran sodium) — Alnylam Netherlands B.V.

  The European Medicines Agency has authorised Oxlumo (lumasiran sodium) for primary hyperoxaluria, an orphan disease, with marketing authoriz…

• FDA approval · 2023-09-29
  FDA Approved: RIVFLOZA — Original Application (Novo Nordisk)

  The FDA approved Rivfloza (nedosiran) from Novo Nordisk through an Original Application (NDA215842) for the treatment of primary hyperoxalur…